Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits

SQ109 is a novel well-tolerated drug candidate in clinical development for the treatment of drug-resistant tuberculosis (TB). It is the only inhibitor of the MmpL3 mycolic acid transporter in clinical development. No SQ109-resistant mutant has been directly isolated thus far in vitro, in mice, or in...

Descripción completa

Detalles Bibliográficos
Autores principales: Egbelowo, Oluwaseun, Sarathy, Jansy P., Gausi, Kamunkhwala, Zimmerman, Matthew D., Wang, Han, Wijnant, Gert-Jan, Kaya, Firat, Gengenbacher, Martin, Van, Nhi, Degefu, Yonatan, Nacy, Carol, Aldridge, Bree B., Carter, Claire L., Denti, Paolo, Dartois, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370215/
https://www.ncbi.nlm.nih.gov/pubmed/34228540
http://dx.doi.org/10.1128/AAC.00024-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370215/
https://www.ncbi.nlm.nih.gov/pubmed/34228540
http://dx.doi.org/10.1128/AAC.00024-21

Ejemplares similares